MedPath

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Phase 2
Active, not recruiting
Conditions
Kidney Transplant Rejection
Interventions
Registration Number
NCT05983770
Lead Sponsor
Eledon Pharmaceuticals
Brief Summary

This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.

Detailed Description

This study is a randomized, multicenter, open-label, active control study to evaluate the safety and efficacy of AT-1501 compared with tacrolimus in the prevention of rejection in patients undergoing kidney transplantation. Up to 120 de novo kidney transplant recipients will receive rATG induction with corticosteroids (CS), and mycophenolate as maintenance therapy, and will be randomized 1:1 to receive either AT-1501 or tacrolimus.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Male or female ≥ 18 years of age
  • Recipient of their first kidney transplant from a living or deceased donor
  • Agree to comply with contraception requirements during and for at least 90 days after the last administration of study drug
Exclusion Criteria
  • Induction therapy, other than study assigned rATG, planned as part of initial immunosuppressive regimen

  • Currently treated with any systemic immunosuppressive regimen, including immunologic biologic therapies

  • Currently treated with corticosteroids other than topical or inhaled corticosteroids

  • Will receive a kidney with an anticipated cold ischemia time of > 30 hours

  • Will receive a kidney from a donor that meets any of the following:

    • 5a. Donation after Cardiac Death (DCD) criteria; Or
    • 5b. Kidney Donor Profile Index (KDPI) of > 85%; Or
    • 5c. Is blood group (ABO) incompatible
  • Medical conditions that require chronic use of systemic corticosteroids or other immunosuppressants

  • History of a thromboembolic event, known hypercoagulable state, or condition requiring long term anticoagulation

  • Positive T- or B-cell crossmatch that is due to HLA antibodies or presence of a DSA at Screening

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InvestigativeAT-1501AT-1501 monoclonal antibody targeting CD40L given as an IV infusion
ComparatorTacrolimusTacrolimus administered BID, targeting a whole blood trough concentration of 6-12 ng/mL until Month 6, and 6-8 ng/mL thereafter
Primary Outcome Measures
NameTimeMethod
eGFR at 12 monthsAssessed from date of transplant through Day 364 (Month 12)

Estimated Glomerular Filtration Rate (eGFR) at 12 months post-transplant

Secondary Outcome Measures
NameTimeMethod
NODAT at 12 months post-transplantAssessed from date of transplant through Day 364 (Month 12

The proportion of new onset diabetes after transplant (NODAT) at 12 months post-transplant

The proportion of patient and graft survival at 12 months post-transplantAssessed from date of transplant through Day 364 (Month 12)

Patient and graft survival are defined as either A) Death, B) re-transplantation or C) Requirement for regular dialysis

BPAR-free patient and graft survival at 12 months post-transplantThe proportion of BPAR-free patient and graft survival at 12 months post-transplant

Assessed from date of transplant through Day 364 (Month 12)

BPAR at 12 monthsAssessed from date of transplant through Day 364 (Month 12)

The proportion of BPAR at 12 months

Trial Locations

Locations (56)

Tulane Medical Center

🇺🇸

New Orleans, Louisiana, United States

University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

Johns Hopkins University

🇺🇸

Baltimore, Maryland, United States

Massachusetts General Hospita;

🇺🇸

Boston, Massachusetts, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

University of Wisconsin Health

🇺🇸

Madison, Wisconsin, United States

Fiona Stanley Hospital

🇦🇺

Perth, Western Australia, Australia

Fundação Oswaldo Ramos - Hospital do Rim

🇧🇷

São Paulo, Brazil

Hospital das Clínicas da Faculdade de Medicina de São Paulo

🇧🇷

São Paulo, Brazil

St. Paul's Hospital

🇨🇦

Vancouver, British Columbia, Canada

CHU Grenoble-Alpes - Hopital Nord Michallon

🇫🇷

Grenoble, France

Centre Hospitalier Universitaire Dupuytren

🇫🇷

Limoges, France

CHU de Toulouse - Hopital de Rangueil

🇫🇷

Toulouse, France

CHRU Tours - Hopital Bretonneau

🇫🇷

Tours, France

Charite Universitatsmedizin Berlin

🇩🇪

Berlin, Germany

Hospital Universitari Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital Clinic de Barcelona

🇪🇸

Barcelona, Spain

Hospital del Mar - Parc de Salut Mar

🇪🇸

Barcelona, Spain

Hospital Germans Trias i Pujol

🇪🇸

Barcelona, Spain

Hospital Universitari de Bellvitge

🇪🇸

Barcelona, Spain

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

Keck School of Medicine of USC

🇺🇸

Los Angeles, California, United States

University of California, Irvine Medical Center

🇺🇸

Orange, California, United States

University of California, Davis Medical Center

🇺🇸

Sacramento, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

University of Colorado Hospital

🇺🇸

Aurora, Colorado, United States

Medstar Georgetown University Hospital

🇺🇸

Washington, District of Columbia, United States

Tampa General Hospital

🇺🇸

Tampa, Florida, United States

Emory University Hospital

🇺🇸

Atlanta, Georgia, United States

Augusta University

🇺🇸

Augusta, Georgia, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Loyola University Medical Center

🇺🇸

Maywood, Illinois, United States

Indiana University School of Medicine

🇺🇸

Indianapolis, Indiana, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

University of Louisville

🇺🇸

Louisville, Kentucky, United States

Brigham and Women's Hospital

🇺🇸

Boston, Massachusetts, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

University of Minnesota Medical Center

🇺🇸

Minneapolis, Minnesota, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Washington University in St. Louis

🇺🇸

Saint Louis, Missouri, United States

University of Nebraska Medical Center

🇺🇸

Omaha, Nebraska, United States

New York University Langone Health - Tisch Hospital

🇺🇸

New York, New York, United States

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

University of Pittsburgh Medical Center

🇺🇸

Harrisburg, Pennsylvania, United States

Columbia University Irving Medical Center / New York Presbyterian Hospital

🇺🇸

New York, New York, United States

Duke University Medical Center

🇺🇸

Durham, North Carolina, United States

University of Cincinnati Medical Center

🇺🇸

Cincinnati, Ohio, United States

UT Southwestern

🇺🇸

Dallas, Texas, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

University of Washington Medical Center

🇺🇸

Seattle, Washington, United States

Royal Adelaide Hospital

🇦🇺

Adelaide, South Australia, Australia

University of Alberta Hospital

🇨🇦

Edmonton, Alberta, Canada

Vancouver General Hospital

🇨🇦

Vancouver, British Columbia, Canada

Hopital de Bois-Guillaume

🇫🇷

Bois-Guillaume, France

Groupe Hospitalier Pellegrin

🇫🇷

Bordeaux, France

Henri Mondor Hospital

🇫🇷

Créteil, France

© Copyright 2025. All Rights Reserved by MedPath